Literature DB >> 16757699

Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis.

Pamela M Marcus1, Erik J Bergstralh, Mark H Zweig, Ann Harris, Kenneth P Offord, Robert S Fontana.   

Abstract

BACKGROUND: A troubling aspect of cancer screening is the potential for overdiagnosis, i.e., detection of disease that, in the absence of screening, would never have been diagnosed. Overdiagnosis is of particular concern in lung cancer screening because newer screening modalities can identify small nodules of unknown clinical significance. Previously published analyses of data from the Mayo Lung Project, a large randomized controlled trial conducted among 9211 male cigarette smokers in the 1970s and early 1980s indicated that overdiagnosis might exist in lung cancer screening. At the end of follow-up (July 1, 1983), no difference in lung cancer mortality was observed, but an excess of 46 cases in the intervention arm suggested overdiagnosis. Because that excess could instead have resulted from short follow-up time, we investigated this possibility by conducting long-term lung cancer incidence follow-up.
METHODS: We investigated the lung cancer status through 1999 of the 7118 participants in the Mayo Lung Project who were alive and without diagnosed lung cancer in 1983 by use of medical records, surveys mailed to participants or next-of-kin, and state death certificates.
RESULTS: Information was available for 6101 participants, including 811 with inconclusive lung cancer status. From November 1971 through December 31, 1999, 585 participants in the intervention arm and 500 in the usual-care arm were diagnosed with lung cancer.
CONCLUSIONS: The persistence of excess cases in the intervention arm after 16 additional years of follow-up provides continued support for overdiagnosis in lung cancer screening.

Entities:  

Mesh:

Year:  2006        PMID: 16757699     DOI: 10.1093/jnci/djj207

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  54 in total

Review 1.  Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art.

Authors:  M Zompatori; M Mascalchi; F Ciccarese; N Sverzellati; U Pastorino
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

Review 2.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

3.  National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.

Authors:  Edward F Patz; Neil E Caporaso; Steven M Dubinett; Pierre P Massion; Fred R Hirsch; John D Minna; Constantine Gatsonis; Fenghai Duan; Amanda Adams; Charles Apgar; Rosa M Medina; Denise R Aberle
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

4.  Computed tomography screening for lung cancer.

Authors:  Pamela M McMahon; David C Christiani
Journal:  BMJ       Date:  2007-02-10

5.  Screening for lung cancer with low-dose computed tomography.

Authors:  Anthony B Miller
Journal:  Oncologist       Date:  2013-08-05

6.  Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

7.  [Screening: prerequisites].

Authors:  M Hoffmeister; U Haug; H Brenner
Journal:  Internist (Berl)       Date:  2008-06       Impact factor: 0.743

8.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

9.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

10.  Cost of a 5-year lung cancer survivor.

Authors:  S W Duffy
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.